Ardaman Shergill to Combined Modality Therapy
This is a "connection" page, showing publications Ardaman Shergill has written about Combined Modality Therapy.
Connection Strength
0.281
-
ASO Visual Abstract: Fragmentation of Care in Patients with Peritoneal Metastases Undergoing Cytoreductive Surgery. Ann Surg Oncol. 2024 01; 31(1):657-658.
Score: 0.043
-
Fragmentation of Care in Patients with Peritoneal Metastases Undergoing Cytoreductive Surgery. Ann Surg Oncol. 2024 Jan; 31(1):645-654.
Score: 0.042
-
Doublet vs. Triplet Systemic Chemotherapy for High Grade Appendiceal Adenocarcinoma with Peritoneal Metastases. J Gastrointest Surg. 2023 11; 27(11):2560-2562.
Score: 0.041
-
Role of Tumor-informed Personalized Circulating Tumor DNA Assay in Informing Recurrence in Patients With Peritoneal Metastases From Colorectal and High-grade Appendix Cancer Undergoing Curative-intent Surgery. Ann Surg. 2023 12 01; 278(6):925-931.
Score: 0.041
-
PI3K Pathway Alterations in Peritoneal Metastases are Associated with Earlier Recurrence in Patients with Colorectal Cancer Undergoing Optimal Cytoreductive Surgery. Ann Surg Oncol. 2023 May; 30(5):3114-3122.
Score: 0.040
-
Survival in Total Preoperative vs. Perioperative Chemotherapy for Patients with Metastatic High-Grade Appendiceal Adenocarcinoma Undergoing CRS/HIPEC. J Gastrointest Surg. 2022 12; 26(12):2591-2594.
Score: 0.039
-
Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma. Ann Surg Oncol. 2021 Mar; 28(3):1777-1785.
Score: 0.034